ArticleAAPS PharmSciTech2026
Breaking Barriers: Intranasal Microemulsions for the Efficient Nose-to-brain Delivery of Glycyrrhetinic Acid.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herbal drugs have been investigated for multiple neurodegenerative diseases because of their multi-targeted mechanisms of action and relatively low toxicity profile. However, due to their unfavorable physicochemical properties that limit their action, nanocarriers are warranted to enhance their delivery and hence their therapeutic effect. In this study, an intranasal microemulsion (ME) of the lipophilic molecule glycyrrhetinic acid (GA), a triterpenoid derived from licorice root that is widely known for its antioxidant and anti-inflammatory properties, was developed for the treatment of Alzheimer's disease (AD). Pseudo-ternary phase diagrams were constructed and the prepared ME systems were optimized using Simplex lattice mixture experimental design. The selected loaded lauroglycol MEs (GA-ME LG) were of droplet size 5.61 ± 0.01 nm and PDI of 0.521 ± 0.032. They showed a significantly high physical stability up to 3 months at room temperature and in the refrigerator. The ex vivo permeation study across sheep nasal mucosa revealed that GA-loaded ME LG exhibited a significant increase in steady-state flux after 8 h compared to GA suspension by 5.67-fold (p < 0.05). SCOP-induced memory impairment in rats was ameliorated by intranasal injection of GA ME LG at a concentration of 1 mg/kg, in a comparable way to the oral route (at a dosage 50 times higher than MEs) (p < 0.05). Additionally, GA ME LG counteracted SCOP-induced oxidative damage (p < 0.05). Collectively, GA-loaded MEs can deliver GA to the brain efficiently and might offer potential treatment for AD patients.
Indexed as
Identifiers
41735609What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.